Spark Therapeutics Financials

Spark Therapeutics Stock Summary

Spark Therapeutics competes with Noble Plc, NL Industries, AKITA Drilling, Patterson UTI, and Ecovyst. Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 368 people.

Spark Therapeutics Key Financial Ratios

Generally speaking, Spark Therapeutics' financial ratios allow both analysts and investors to convert raw data from Spark Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Spark Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Spark Therapeutics reports annually and quarterly.

Spark Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Spark Therapeutics's current stock value. Our valuation model uses many indicators to compare Spark Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spark Therapeutics competition to find correlations between indicators driving Spark Therapeutics's intrinsic value. More Info.Spark Therapeutics is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Spark Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Spark Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spark Therapeutics' earnings, one of the primary drivers of an investment's value.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.